Unresolved issues in diffuse large B-cell lymphomas.

@article{Murawski2010UnresolvedII,
  title={Unresolved issues in diffuse large B-cell lymphomas.},
  author={Niels Murawski and Carsten Zwick and Michael Pfreundschuh},
  journal={Expert review of anticancer therapy},
  year={2010},
  volume={10 3},
  pages={387-402}
}
For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the 'gold standard' for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs). After the demonstration of rituximab's single-agent activity in DLBCL, a pivotal trial in elderly patients demonstrated that combining rituximab with eight applications of CHOP significantly improved complete remission rates, and event-free and overall… CONTINUE READING